Video

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

Author(s):

Edith A. Perez, MD,

In Partnership With:

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment.

Related Videos
David A. Braun, MD, PhD
Bradley McGregor, MD,
Francisco J. Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine – Lymphoma, director, Lymphoma Research, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Monica H. Vetter, MD
Ian Krop MD, PhD
Marco Davila, MD, PhD
Yvonne Mowery, MD, PhD, associate professor, Department of Radiation Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, radiation oncologist, Mary Hillman Jennings Radiation Oncology, UPMC Shadyside
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
FDA
January 20th 2025

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

Roxana S. Dronca, MD, professor, oncology, consultant, Division of Hematology/Oncology, Department of Internal Medicine, director, Mayo Clinic Comprehensive Cancer Center
January 20th 2025

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

FDA
January 17th 2025

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Breast cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 14th 2025

Researchers Resolve Uncertainty in BRCA2 Testing, Improving Cancer Risk Assessment and Patient Care

Roxana S. Dronca, MD
January 13th 2025

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management